Raytheon Technologies Corp vs Tilray Brands Inc — how do they compare? Raytheon Technologies Corp trades at $198 (market cap $267.95B), while Tilray Brands Inc trades at $4.21 (market cap $591.60M). The key difference: Raytheon Technologies Corp is far larger — about 452.9× Tilray Brands Inc's market cap, and Raytheon Technologies Corp pays a 1.47% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| RTX | TLRY | |
|---|---|---|
Market Cap | $267.95B | $591.60M |
Sector | Industrials | Health |
52-Week High | $225.49 | $21.00 |
52-Week Low | $155.00 | $3.88 |
Enterprise Value | $298.50B | $758.73M |
Dividend Yield | 1.47% | — |
Signals from Pluang's Aura AI — not financial advice
RTX trades at $197.55, down 1.61% today, but maintains a bullish technical outlook with strong support near $197 and resistance at $200. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.75. Revenue growth accelerated to $88.6 billion in 2025, with net income reaching $6.73 billion. Recent contract wins include a $515 million U.S. Navy radar award announced June 3, 2026.
Outlook remains positive with 65% analyst buy ratings and a $235.33 price target implying 19% upside. Key risks include execution challenges in scaling munitions production and dependence on defense budgets. Strong cash flow generation and expanding margins support continued dividend payments, with the next $0.73 dividend payable September 3, 2026.
TLRY trades at $4.30, down 4.44% today, reflecting ongoing investor skepticism despite record fiscal 2026 revenue of $915 million. The stock shows bearish technical signals with key support at $4.00, while fundamentals reveal significant challenges including negative net income margins (-13.26%) and consecutive earnings misses. Recent developments include strategic partnerships expansion in New York and California spirits markets and increased medical cannabis production capacity to 275 metric tonnes.
TLRY faces substantial execution risks with persistent losses and negative cash flow, though trading below book value (P/B 0.37) offers potential value. Analyst consensus remains cautious with 65% hold ratings, while regulatory progress in cannabis remains a key catalyst. The stock requires successful margin improvement and U.S. regulatory clarity for sustained recovery.
Trailing returns across standard periods
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →